Understanding immune response in sepsis and septic shock

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the dynamics of the immune response in patients suffering from sepsis and septic shock. Utilizing advanced techniques such as transcriptomics, flow-cytometry, and cytokine analysis, the study seeks to provide a detailed characterization of immune homeostasis in these critical conditions. By examining the immune profiles of patients within the first 24 hours of diagnosis, the research intends to uncover insights that could inform future therapeutic strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* sepsis/septic shock (SEPSIS-3)
* age ≥18
* informed consent
* inclusion within first 24hrs after development/diagnosis of septic shock

Exclusion Criteria:

* disagreement of the patient or legal representative with the entry into the study
* patients with primary or secondary immunodeficiency
* presence of active haematological malignancy or an active non-haematological malignancy

Where it's running

• Medical ICU, 1st Dept. of Internal Medicine, Teaching Hospital in Pilsen
  Pilsen, Česká Republika, Czechia Recruiting

Study contacts

• Principal investigator: Thomas Karvunidis, MD, PhD — Carles University Teaching Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic
• Study coordinator: Thomas Karvunidis, MD, Ph.D.
• Email: karvunidist@fnplzen.cz
• Phone: +420 377 103 173

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care

  This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07922213

• Early detection of sepsis-related blood clotting problems in severe burn patients

  This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.

  Recruiting Center for Traumatology and Major Burns, Ben Arous · Tunis · NCT07914205

• Neutrophil EMR3 as a biomarker for sepsis in ICU patients

  Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07896018

• Thymalfasin added to standard care for adults with sepsis and immune dysfunction

  This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07866118

• Multicenter group study of sepsis and ARDS in China

  This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.

  Recruiting at 24 sites Shanghai Zhongshan Hospital · Xiamen, Fujian and 23 other locations · NCT07863908

• Non-invasive hemodynamic guidance for sepsis care on medical wards

  This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.

  Recruiting at 2 sites Regione del Veneto - AULSS n. 7 Pedemontana · Pisa, Pisa and 1 other locations · NCT07863323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.